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Abstract
Background: Several studies have shown that muscarinic cholinergic agonists cause
antinociception in humans and animals when given by both spinal and non-spinal parenteral routes.
It is uncertain which subtype of muscarinic receptor is involved in spinally mediated antinociceptive
effects caused by these drugs. The cholinergic receptor agonists McN-A-343 (M1 selective; 3.89 to
389 nmol) and carbachol (non-selective; 0.029 to 29 nmol) were used in a rat acute pain model to
investigate the involvement of M1 and non-M1 subtypes in spinally mediated antinociception. The
drugs were injected intrathecally and results from experiments in which drug actions were carefully
confined to the spinal cord were used to construct agonist dose response curves.
Results: McN-A-343 frequently diffused rostrally to the brain, away from the lumbosacral site of
injection. Thus, in spite of its receptor subtype selectivity, McN-A-343 is a poor probe to use in
attempting to identify receptor subtypes involved in spinal cord antinociceptive systems. However,
in some experiments McN-A-343 caused spinally mediated antinociception assessed by the
electrical current threshold test. Antinociception assessed by the tail flick latency test with
intrathecal McN-A-343 was observed and found to involve supraspinal mechanisms. Carbachol
caused spinally mediated antinociception assessed by both electrical current threshold and tail flick
latency.
Conclusions: The results suggest that M1 receptors are involved in spinally mediated
antinociception revealed by electrical current threshold; other cholinergic receptors (non-M1) are
involved in thermal antinociception at the spinal cord. This contrasts with previous work on spinally
mediated cholinergic antinociception. These differences are believed to be due to difficulties in
restricting the action of these drugs to the spinal cord.
Background
Muscarinic cholinergic agonists as well as cholinesterase
inhibitors possess antinociceptive activity in animal tests
[1–5]. Harris et al. [4] showed that the nonselective mus-
carinic agonist oxotremorine and the cholinesterase in-
hibitor physostigmine were as efficacious as morphine in
the mouse tail flick. It is important to note, in the light of
the current paper and other reports that acetylcholine, ad-
ministered intracerebroventricularly, has been shown to
cause antinociception assessed with the mouse tail-flick
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carinic antagonists but not by opioid antagonists [6]. That
observation suggests that muscarinic antinociception as-
sessed with noxious heat can be mediated directly
through muscarinic receptors and not indirectly through
opioid systems and furthermore that the antinociceptive
effects of these compounds can be caused by drug action
at receptors in the brain.
Several studies have tried to investigate the muscarinic re-
ceptor subtypes involved in the antinociception evoked
by muscarinic agonists. Bartolini et al. [7] suggested that
M1 receptors were involved. By contrast Dawson et al. [8]
suggested that antinociception in the mouse tail flick was
mediated by M1 or M3 receptors. More recently, Iwamoto
and Marion (1993) [9], working with intrathecally inject-
ed muscarinic agonists, suggested that M1 and/or M2 re-
ceptor subtypes were involved in the spinal cord. Much of
this work has been clouded by doubts about the receptor
selectivity of agonist and antagonist drugs that were used.
That is also true for the novel muscarinic agonist McN-A-
343 (M1-agonist) that was used in the study reported here.
However, a recent study confirmed that McN-A-343 is a
selective M1 agonist [10]. One study used that selectivity
of McN-A-343, which was injected intrathecally, to deter-
mine the receptor subtype involved with cholinergic anti-
nociception at the level of the spinal cord. The effects on
nociceptive thresholds to noxious heat were assessed fol-
lowing McN-A-343 (M1-agonist), carbachol (non-selec-
tive muscarinic cholinergic agonist) and neostigmine
(cholinesterase inhibitor), given intrathecally alone and
in combination with antagonists [11]. Using this ap-
proach it was concluded that muscarinic agonists were po-
tent spinal analgesics, especially those specific for M1 and/
or M3 receptor sub-types [11]. Thus this study seemed to
confirm much of the previous work.
However, in all of the above-cited work it is uncertain how
much of the antinociceptive effects observed were due to
actions of the drugs at the spinal cord level. Given that
muscarinic agonists may cause antinociception by interac-
tions with receptors in the brain [6] it is possible that even
an intrathecally administered drug can cause antinocicep-
tive effects by actions at a brain site by spreading away
from its spinal site of injection towards more rostral struc-
tures, including the brain. Unless suitable experimental
controls are performed to assure the experimenter that
drug action is confined to the spinal cord, erroneous con-
clusions may be drawn about the site of action of a drug
and thus the involvement of spinal cord receptors. This
can influence greatly the side effect profile of a drug and
also the conclusion on its suitability for spinal administra-
tion to humans.
A technique described by Goodchild and Serrao in 1987
enables the site of drug action, brain or spinal cord, re-
sponsible for the antinociceptive effects following intrath-
ecal injection of a drug to be determined. This is achieved
by measurement of nociceptive threshold using electrical
current (ECT) at caudal and rostral skin sites [12]. The ECT
is determined at a neck and tail skin site and then an anti-
nociceptive drug is administered intrathecally at the level
of the lumbar and sacral segments of the spinal cord re-
sponsible for the innervation of caudal dermatomes in-
cluding the tail. If the drug remains confined to the caudal
segments of spinal cord then a rise in tail ECT is noted
with no effect on neck ECT. If the drug does spread rostral-
ly to higher levels of spinal cord or brain then a rise in ECT
is observed at both tail and neck skin sites. This technique
may be combined with concomitant tail flick latency
(TFL) measurements to show that a drug affecting this no-
ciceptive modality also produces its effects by a spinal
cord action. In the experiments reported in this paper the
spinal antinociceptive component of two cholinergic
drugs (McN-A-343 and carbachol) was investigated in this
acute pain model.
Results
Antinociceptive efficacy of intrathecal McN-A-343
The results of all experiments in this part of the study refer
to rats that had a positive result to the lignocaine test both
after catheter implantation surgery and after each experi-
ment. Thus in all experiments McN-A-343, was adminis-
tered intrathecally. This study, as in previous studies using
these protocols, revealed that nociceptive thresholds
measured each day prior to drug administration remained
stable with no significant progressive increase or decrease
that might indicate residual drug effects from one day to
the next or progressive neurological damage.
Figure 1
Experimental protocol for nociceptive testing This fig-
ure shows the experimental protocol used in all experi-
ments. X values represent ECT (tail and neck) and TFL
measurements made before intrathecal (IT) drug administra-
tion and Y values represents measurements made after drug
administration.
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of antinociception when assessed by the ECT test that was
maintained for the duration of the experiment. Frequently
there was a rise in ECT (n) indicating rostral spread of
McN-A-343. Figure 2 shows dose response curves for ECT
(t), ECT (n) and TFL including all data. There was no dose
of McN-A-343 that caused a rise in ECT (t) without a con-
comitant rise in ECT (n) in some measurements during
the experiment. It was because of this that the data sorting
procedure was used to exclude those measurements where
there was significant antinociception at the neck skin site
(statistically compared with 8% dextrose control) indica-
tive of rostral spread at least as far as the cervical spinal
cord and thus possibly to the brain. This allowed con-
struction of dose response relationships in which only spi-
nally mediated effects were included. These dose response
curves are shown in figure 3. As the dose of McN-A-343
was increased the number of measurements in which
there was no significant rise in ECT (n) decreased com-
pared with the total number of measurements taken for
that dose. After the exclusion of those measurements
where rostral spread had occurred so that there was no sig-
nificant antinociceptive effect of McN-A-343 on ECT (n),
there was a significant dose dependent increase in ECT (t)
(p < 0.05, Student's t-test). However there was no signifi-
cant spinally mediated antinociception observed with the
TFL test. The highest dose (389 nmol) of McN-A-343 was
found to cause paralysis making impossible the determi-
nation of TFL as a measure of antinociception.
Figure 2
Dose response curves for intrathecal carbachol, all
data All ECT (neck and tail) and TFL values recorded in the
rats that received intrathecal doses of carbachol that subse-
quently had positive lignocaine tests. Values for each testing
site and modality have been combined at each dose of carba-



















































Dose response curves for the spinally mediated anti-
nociceptive effects of intrathecal McN-A-343 The val-
ues for ECT (neck, panel A; tail, panel B) and TFL (panel C)
are shown on a scatter plot against dose of intrathecal McN-
A-343. Only the results from testing times when there was
no significant rise in ECT (n) values are shown. These values
have been subjected to a logistic regression shown by the
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As with McN-A-343 IT carbachol caused a rapid rise in
both ECT (t) and frequently ECT (n) indicative of rostral
spread of the drug in many experiments. Figure 4 shows
dose response curves for ECT (t), ECT (n) and TFL includ-
ing all data. There was no dose of carbachol that caused a
rise in ECT (t) without a concomitant rise in ECT (n) for
some measurements during the experiment. Therefore,
the same data sorting was applied to carbachol that was
applied to McN-A-343 to exclude those measurements
where rostral spread of the drug had occurred. When spi-
nally confined (i.e. when there was an ECT value in the
neck that was not significantly different from the neck
ECT values obtained with 8% dextrose controls) there was
significant antinociception when assessed by ECT at the
tail skin site (figure 5; p < 0.01, at the highest dose) al-
though there was a large scatter of results and a shallow
dose response regression line. By contrast a clear dose re-
sponse curve was obtained for TFL. A logistic curve fit al-
lowed calculation of the ED50 for the spinal action of
intrathecal carbachol on TFL (1.4 nmol, coefficient of var-
iation = 5.6%; figure 5).
Side effects of intrathecal McN-A-343 and carbachol
A number of significant side effects were noted with the
intrathecal administration of the cholinergic agonist
drugs. McN-A-343 at doses of 3.89 nmol and 38.9 nmol
caused very few side effects, but at the highest dose of 389
nmol where rostral spread was more common many side
effects were noted. These ranged from paralysis (28%),
death (5%, from respiratory arrest), sedation or tachyp-
noea (11%), and tail autotomy (11%). In contrast to
McN-A-343 the only side effect noted with the use of car-
bachol was tail autotomy. This autotomy did not appear
to be dose dependent.
Discussion
The major obstacle encountered in this study was restrict-
ing the action of drugs administered to the lumbosacral
segments of the spinal cord. Many drugs given intrathecal-
ly do eventually reach the brain via the CSF resulting in
drug action at both sites. This is important since many
studies have reported that activation of muscarinic cholin-
ergic receptors throughout the CNS causes antinocicep-
tion [9,13–17].
Previous studies have concluded that M1 and possibly M2
and/or M3 receptors are involved with spinally mediated
antinociception [9,11]. These studies used noxious heat as
the nociceptive test and the results seem to be at odds with
the observations made in gene knockout animals. In M2
gene knockout studies antinociception following mus-
carinic agonists was markedly reduced implying that M2
receptors are responsible for these effects [18]. Autoradi-
ography studies have shown both M1 and M2 muscarinic
receptors in laminae II and III of the spinal cord [19].
Functional studies have suggested that the M1 receptor
subtype is responsible for post-synaptic muscarinic anti-
nociception and a recent systematic study by Naguib &
Yaksh confirmed this [11,20,21]. These results seem to
disagree with an autoradiography study that concluded
that there were no M1 muscarinic receptors in rat spinal
cord [22]. However this result relies on the selectivity for
the subtypes of muscarinic receptor of the agonist and an-
tagonist drugs used. Thus the background levels of M1 re-
ceptor binding reported by Hoglund and Baghdoyan may
actually indicate that there are significant numbers of M1
receptors in the rat spinal cord [22]. Thus the nature and
function of muscarinic receptor subtypes involved with
spinally mediated antinociception is still uncertain.
In all of the above-cited in-vivo work it is uncertain how
much of the antinociceptive effects observed were due to
actions of the drugs at the spinal cord level. Given that
muscarinic agonists may cause antinociception by interac-
tions with receptors in the brain [6] it is possible that even
an intrathecally administered drug may spread away from
its site of injection towards more rostral structures, includ-
ing the brain and thus cause antinociception. Unless suit-
able experimental controls are in place to assure the
experimenter that drug action is confined to the spinal
cord, erroneous conclusions may be drawn about the site
of action of a drug and the involvement of specific spinal
cord receptors. These have to be performed in every exper-
iment. The model of intrathecal cannulation that is used
commonly was shown to deliver drugs selectively to the
spinal cord when the method was first described [23].
Figure 4
Dose response curves for intrathecal McN-A-343, all
data All ECT (neck and tail) and TFL values recorded in the
rats that received intrathecal doses of McN-A-343 that sub-
sequently had positive lignocaine tests. Values for each test-
ing site and modality have been combined at each dose of
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model is used and it is still possible in individual experi-
ments or in a series of experiments that the catheters could
be misplaced or the drugs injected down them might
spread rostrally to the brain.
The observations of increases in ECT thresholds in the
neck show that drugs injected more caudally at the level of
the lumbosacral spinal cord can alter neck ECT measure-
ments and thus they are an indicator of rostral spread of
the drug away from lumbosacral segments. In the experi-
ments reported in this paper it must be remembered that
even if an antinociceptive effect is observed at the neck
skin site this does not positively indicate that the drug has
reached the brain because cervical spinal cord segments
supply the neck skin site. An increase in ECT (n) does
however provide strong evidence that the administered
drug has spread rostrally in the spinal cord and thus one
cannot be sure that it was confined totally to the spinal
cord and that it did not reach the brain to exert a suprasp-
inal effect.
Rostral spread of the cholinergic agonist drugs occurred
frequently because of their high water solubility. In order
to restrict the movement of drug solution in the CSF the
drug was dissolved in an 8% dextrose solution in the ex-
periments reported in this paper. This has a higher specific
gravity than CSF and when combined with elevation of
the animal's body on an inclined plane head up, it pro-
motes confinement of the drug by gravity to the caudal
segments of the spinal cord. In spite of this manoeuvre,
rapid rostral spread of the drugs still occurred within five
minutes of administration in some animals. Hence the
data sorting process using the scattergram was used to ex-
tract those measurements where it was confirmed by the
ECT (n) measurements that drug effects were confined to
the caudal segments of the spinal cord. Values of ECT
(tail) and TFL were used for construction of spinally me-
diated antinociception dose response curves only if their
corresponding ECT (n) was not statistically different from
ECT (n) values obtained after intrathecal vehicle. The
main concern with this approach is the pooling of all post
drug measurements over the 30 minutes period instead of
the period of peak effect. This is justified given the rapid
onset and prolonged effects of these drugs. Pooling of all
such measurements at each dose therefore results in an es-
timate of the average antinociceptive effect over 30 min-
utes after intrathecal drug.
Antinociceptive efficacy of intrathecal McN-A-343
The first part of the study examined the spinally mediated
antinociceptive efficacy of McN-A-343. McN-A-343 has
been proposed as a highly selective M1 agonist [24] and
this was confirmed in a recent study designed to settle
doubts about the selectivity of McN-A-343 [10]. The re-
Figure 5
Dose response curves for the spinally mediated anti-
nociceptive effects of intrathecal carbachol The values
for ECT (neck, panel A; tail, panel B) and TFL (panel C) are
shown on a scatter plot against dose of intrathecal carbachol.
Only the results from testing times when there was no signif-
icant rise in ECT (n) values are shown. These values have
been subjected to a logistic regression shown by the continu-
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BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/20sults reported herein suggest that a spinal cord action of
McN-A-343 causes significant dose dependent antinocice-
ption when determined by ECT (t). Despite the antinoci-
ceptive effect of McN-A-343 on ECT there was no
antinociceptive effect of McN-A-343 assessed by TFL. At
the highest dose (389 nmol) of McN-A-343 TFL was ele-
vated maximally (100% MPE). These animals had suf-
fered hind limb paralysis and so were unable to flick their
tail. Thus the 100% MPE measurement may be due to pa-
ralysis rather than antinociception although an antinocic-
eptive effect at that dose cannot be ruled out. Paralysis did
not affect ECT readings because vocalisation was the re-
sponse and also the end point. At the 389 nmol dose the
rats did vocalise in ECT tests at the tail skin site suggesting
that tail anaesthesia had not occurred. This result is differ-
ent to the findings of Naguib et al [11]. They did not re-
port any side effects at the 389 nmol dose of McN-A-343
suggesting that perhaps they were administering the drug
epidurally. This would decrease the amount of drug deliv-
ered to the intrathecal space and thus causing an effective
rightward shift of the dose response. Many other side ef-
fects were observed with the use of McN-A-343 at the 389
nmol dose that were not reported by Naguib et al. The side
effects include death, sedation, tachypnoea, tachycardia,
tail autotomy as well as hind limb paralysis which are easy
to observe and therefore to report. This again suggests that
perhaps epidural doses were given in that study [11] and
that could explain why their conclusion about M1 recep-
tor involvement in TFL effects differs from the conclusion
made after the experiments reported in this paper.
The experiments reported in this paper suggest that spinal
cord M1 receptors mediate antinociception assessed by
the ECT test. This conclusion is based upon the selectivity
of McN-A-343 for that receptor subtype and there is some
controversy about this. Although there is the suggestion
that it also binds with M2 and M3 receptor subtypes this
has been refuted by recent studies [10]. However the sug-
gestion for involvement of the M1 subtype in spinal cord
by the current study does disagree with binding studies
that concluded that there are no M1 receptors in the rat
spinal cord [22]. Thus it is possible if McN-A-343 is not to-
tally selective for the M1 subtype, that the ECT effects of
McN-A-343 at the level of the spinal cord are mediated by
M3 receptors.
Even if McN-A-343 were a very selective probe for M1 re-
ceptors, it does not seem to be a good probe to investigate
the involvement of M1 receptors in spinal cord antinocic-
eptive mechanisms. The high water solubility of this com-
pound led frequently to rostral spread. TFL only rose
when McN-A-343 had spread rostrally to elevate ECT(n).
Thus TFL antinociception following intrathecal McN-A-
343 is a supraspinal effect. Even at the supraspinal level
the involvement of M1 receptors in the TFL responses after
McN-A-343 is in doubt because it has been shown in M2
gene knockout mice that the antinociceptive effects of
muscarinic agonists assessed with the TFL test is markedly
reduced [18]. It is possible that neck ECT values rose fol-
lowing increased intraspinal release of acetyl choline
caused by intrathecal injection of agonist; this has been
shown for carbachol [29]. However this would still indi-
cate spread of the drug away from its site of injection mak-
ing it impossible to be sure of the site of action. It is also
plausible that the negative results in this study for McN-A-
343 may be because M1, M2, M3 oligomeric combination
receptors may be involved [30].
Antinociceptive efficacy of intrathecal carbachol
The second part of this study examined the antinocicep-
tive efficacy of the non-selective cholinergic agonist, car-
bachol. It was found that carbachol caused statistically
significant antinociception assessed by ECT at the tail skin
site when there were no significant changes in ECT (n)
thresholds, although there was great scatter of results and
a shallow dose response curve. There was a classical and
highly significant dose related antinociception for the TFL
test. This antinociceptive effect for TFL occurred at doses
significantly lower than those observed by Naguib et al.
(1997). The ED50 for carbachol on paw flick latency (PFL;
equivalent to TFL) was 29 nmol in Naguib's study whereas
the ED50 in this study for carbachol on TFL was 1.4 nmol.
One explanation for this is that Naguib et al. may have
been giving doses of agonist epidurally.
There are two reasons that point to the fact that previous
studies may have given drugs via catheters that had mi-
grated from the intrathecal space epidurally. The first is
that others using the same drugs and formulations ob-
served none of the side effects noted in this study. The side
effect dose response curve could be shifted rightward if the
drug was given into the epidural space and thus lower
concentrations diffused from there into the subarachnoid
space. The major finding that suggests previous experi-
menters were giving their doses epidurally is that the ob-
served TFL effects of carbachol (ED50 = 1.4 nmol)
occurred at doses approximately twenty times lower than
those used by prior studies (ED50 = 29 nmol) [11]. It is
known that if a catheter is placed epidurally a much larger
dose than the intrathecal dose of lignocaine will be re-
quired to cause the same paralysis.
The ability of intrathecal carbachol to cause thermal anti-
nociception by a spinal cord action contrasts with McN-A-
343 that did not cause thermal antinociception when its
effects were confined to the spinal cord. This means that a
cholinergic receptor other than the M1 subtype may be re-
sponsible for the thermal antinociception caused by car-
bachol. It has been suggested that cholinergic
antinociception may be due to M1 and M2 receptor sub-Page 6 of 9
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eption [25]. This conclusion fits with the study in M2 gene
knockout mice showing that the antinociceptive effects of
muscarinic agonists assessed with the TFL test is markedly
reduced in these animals [18].
Conclusions
In conclusion this study has shown that cholinergic ago-
nists do produce spinally mediated antinociception affect-
ing both electrical and thermal modalities shown by
changes in ECT and TFL. Intrathecal McN-A-343, which
binds with M1 and possibly M3 subtypes of muscarinic re-
ceptors, produces spinally mediated antinociception
when determined by the electrical modality of ECT, but
not by the thermal modality of TFL. The observations of
spinally mediated antinociception assessed with ECT and
TFL following carbachol, when combined with the obser-
vations on the activity of McN-A-343, suggest that non-M1
(probably M2) muscarinic receptors are involved in spinal-
ly-mediated thermal antinociception. There are contradic-
tions between studies setting out to define the muscarinic
receptor subtypes involved with spinal antinociception.
These contradictions probably arise from methodological
differences such as not confirming with appropriate con-
trols, correct intrathecal dosing and confinement of drugs
and their effects to the spinal cord.
Methods
This work was carried out with the permission from the
Monash University Standing Committee On Ethics in An-
imal Experimentation (SCEAE No. B-97-01). In all exper-
iments attention was paid to ethical guidelines for the
investigation of experimental pain in conscious animals
[26].
Intrathecal catheter implantation
Male Wistar rats (140–160 g) were anaesthetised with ha-
lothane in oxygen-enriched air (FiO2 = 0.4) and a Portex
catheter (I.D. 0.28 mm, O.D. 0.61 mm) was implanted
under aseptic conditions into the lumbar subarachnoid
space to lie adjacent to the lower lumbar and sacral seg-
ments of the spinal cord using a method described previ-
ously [12]. After the rats recovered from general
anaesthesia they were observed for normal behaviour and
movement. If there were any signs of neurological dam-
age, such as paralysis, the animal was killed immediately.
Correct placement of the catheter was verified by intrath-
ecal injection of lignocaine (2% 10 µL) into the catheter
followed by 15 µL of saline flush. Correct position was
confirmed if the animal became paralysed in the hind-
limbs within 30 seconds of this local anaesthetic injection
[12]. This test was performed immediately after recovery
from surgery and also after each experiment. Thus, we
were confident that all drugs injected down the catheter
were introduced into the lumbar subarachnoid space. A
minimum of at least 12 hours elapsed between catheter
implantation and nociceptive testing. In previous studies
using these protocols it has been shown that nociceptive
thresholds measured each day prior to drug administra-
tion remain stable with no significant progressive increase
or decrease that might indicate residual drug effects or
neurological damage [12].
Nociceptive tests
Nociceptive thresholds were measured with two tests:
electrical current (ECT) at two skin sites, the neck-ECT (n)
and tail – ECT (t); and noxious heat (tail-flick latency,
TFL) as described previously [27,28]. A series of experi-
ments using these nociceptive tests were performed on
each rat, the first one being on the day after cannulation.
One experiment was performed each day on each rat up to
a maximum of four. The rats were kept in groups of 5 prior
to intrathecal cannulation and then in single boxes in
rooms with a 12-h12 h light/dark cycle. They were al-
lowed free access to food and water throughout. Experi-
ments were carried out in a quiet, darkened environment
to decrease distraction of the animal by extraneous noises
and light.
Electrical current threshold test
Each rat was placed in a plastic restrainer (elevated head
up on an inclined plane at 30°) and all the antinociceptive
tests were performed sequentially every five minutes as
shown in figure 1. Needle electrodes were placed 1 cm
apart in the skin at the base of the neck and wire electrodes
were applied to the surface of the skin 1 cm and 5 cm from
the base of the tail. These pairs of electrodes were connect-
ed alternately to a constant current stimulator (50 Hz; 2
ms pulses; 0.5 s train) in order to measure the ECT at each
skin site. The ECT was the minimum current necessary to
provoke either sharp withdrawal or (more usually) a
squeak. Three consecutive stable (pre-drug injection)
readings (X1, X2, X3) were obtained and then the intrath-
ecal injection of cholinergic drug (McN-A-343 or carba-
chol) was given. The tests were repeated every five minutes
for a further thirty minutes to obtain six post-injection
readings (Y1 – Y6). The responses of individual animals
were standardised because the absolute measurement of
electrical thresholds in mA varied between animals and
even in the same animal at different testing times because
of minor differences in electrode position. The standardi-
sation was achieved by each ECT reading obtained after
the intrathecal injection by the mean of the three corre-
sponding control (pre-injection) readings for that set of
electrodes. This was called the standardised response ex-
pressed as a multiple of control (x control).
Tail flick latency (TFL) test
The tip of the tail was painted black after the animal had
been placed in the restrainer. The heat from 150 w projec-Page 7 of 9
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the time taken for the animal to remove (flick) its tail
from the source of the heat was measured. As with the ECT
test intrathecal drug was injected after three stable read-
ings had been obtained. The three values taken prior to in-
trathecal drug were averaged to give a mean latency (TFL
pre-drug) and each post drug reading (TFL post-drug) was
standardised as a percentage maximum possible effect
(%MPE) as follows:
away from the heat source before the lamp was automati-
cally switched off; this was set at 10 s in order to avoid
burning the tail.
Tail flick latency was always measured before either elec-
trical threshold and the neck threshold was assessed after
the tail measurements. ECT testing of the neck and tail
skin sites was performed in every experiment to determine
that the antinociceptive drug given was confined to the
caudal segments of the spinal cord. For example, a rise in
tail thresholds [ECT (t)] after intrathecal drug, but not
neck thresholds [ECT (n)], proves that the drug is con-
fined in its actions to the caudal segments of the spinal
cord for ECT antinociception and also any concurrent in-
crease in TFL.
Dose response curves for the antinociceptive effects of
McN-A-343 (M1 agonist) and carbachol (non selective
cholinergic agonist) were generated using ECT at neck and
tail skin sites and TFL. McN-A-343 (Research Biochemi-
cals International) was administered intrathecally to 51
rats in 74 experiments at doses 38.9 – 389 nmol (dis-
solved in 5 µL 8% glucose solution). Carbachol (Research
Biochemicals International) was also administered in-
trathecally to 22 rats in 41 experiments at doses 0.29 – 29
nmol (dissolved in 5 µL 8% glucose solution). All intrath-
ecal injections were performed via a Hamilton micro sy-
ringe that was attached to the catheter. Injections were
given in a constant volume of 5 µL of 8% dextrose solu-
tion at 15 µL/min. Only one dose of cholinergic drug was
injected into each rat per day; the order of doses being ran-
dom in those rats that received more than one dose of
drug.
Controls
Twenty-six rats with intrathecal catheters were given 5 µl
intrathecal injections of 8% dextrose solution and ECT
and TFL values were measured as above. These experi-
ments were performed to establish that this vehicle had
no effect on nociceptive thresholds and also to establish a
mean and a scatter around the mean of nociceptive meas-
urements at both skin sites. The latter could be used to test
statistically if any particular threshold measurement taken
after drug administration was significantly different from
control.
Statistics and construction of dose response curves
Both agonist drugs proved difficult to confine in their ac-
tions to the caudal segments of spinal cord, i.e. rises in
neck thresholds were observed frequently. This occurred
in spite of dissolving the drug in a solution that was hy-
perbaric compared with CSF (8% dextrose) and perform-
ing injections with the rat inclined at 30° to the horizontal
("head up") to try to restrict the drug by gravity to caudal
segments of spinal cord. However, the responses to both
drugs were found to be long lasting, i.e. an antinociceptive
effect occurred within five minutes of the intrathecal injec-
tion and it continued throughout the experimental period
of 40 minutes thereafter. It was decided to employ a sta-
tistical method to extract those datum points for ECT (t)
and TFL where there was no significant rise in the ECT (n)
value taken at that time point and to use these data to con-
struct dose response curves.
For each lignocaine positive experiment the %MPE for the
TFL measurements and the values for ECT (t), ECT (n) and
TFL were calculated for each 5 min time point. Thus each
time point after all doses of agonist given in an experi-
ment where the lignocaine test was positive yielded three
values, an ECT (n) with the corresponding ECT (t) and
TFL values. The values of ECT (n) obtained in the control
experiments in which the vehicle was given intrathecally
(8% dextrose, n = 26) were combined to calculate a mean
and 95% confidence intervals. These values were used to
identify ECT neck data that showed no significant change
following intrathecal agonist (within the 95% confidence
intervals around the mean) and thus the corresponding
ECT tail and TFL changes that could be ascribed to a spinal
cord action of the intrathecal drug. Logistic regression (y =
a loge(x)+b) using sums of squares was performed on
these spinal data (where ECT neck value was within the
95% confidence intervals of the neck data in control ex-
periments with 8% dextrose). The resultant line with 95%
%MPE
TFL post - drug TFL pre - drug
cut off time TFL pre - drug
=
( ) − ( )
− ( )
Table 1: Vehicle controls, 8% dextrose Results from control ex-
periments. ECT responses from tail and neck electrodes after 5 
µl intrathecal injections of 8% dextrose.
mean SEM n
ECT tail 1.07 0.01 26
ECT neck 1.03 0.01 26Page 8 of 9
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istered superimposed on a scatter plot of the TFL and ECT
responses that were used to calculate the regression lines.
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